DE69713112D1 - Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen - Google Patents

Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen

Info

Publication number
DE69713112D1
DE69713112D1 DE69713112T DE69713112T DE69713112D1 DE 69713112 D1 DE69713112 D1 DE 69713112D1 DE 69713112 T DE69713112 T DE 69713112T DE 69713112 T DE69713112 T DE 69713112T DE 69713112 D1 DE69713112 D1 DE 69713112D1
Authority
DE
Germany
Prior art keywords
compositions
methods
indolicidine
analogs
treating infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69713112T
Other languages
English (en)
Other versions
DE69713112T2 (de
Inventor
R Fraser
H West
J Krieger
Robert Taylor
Douglas Erfle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biowest Therapeutics Inc
Original Assignee
Micrologix Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micrologix Biotech Inc filed Critical Micrologix Biotech Inc
Publication of DE69713112D1 publication Critical patent/DE69713112D1/de
Application granted granted Critical
Publication of DE69713112T2 publication Critical patent/DE69713112T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE69713112T 1996-08-21 1997-08-21 Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen Expired - Lifetime DE69713112T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2475496P 1996-08-21 1996-08-21
US3494997P 1997-01-13 1997-01-13
PCT/US1997/014779 WO1998007745A2 (en) 1996-08-21 1997-08-21 Compositions and methods for treating infections using analogues of indolicidin

Publications (2)

Publication Number Publication Date
DE69713112D1 true DE69713112D1 (de) 2002-07-11
DE69713112T2 DE69713112T2 (de) 2003-01-30

Family

ID=26698836

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69713112T Expired - Lifetime DE69713112T2 (de) 1996-08-21 1997-08-21 Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
DE69739035T Expired - Lifetime DE69739035D1 (de) 1996-08-21 1997-08-21 Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69739035T Expired - Lifetime DE69739035D1 (de) 1996-08-21 1997-08-21 Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen

Country Status (9)

Country Link
US (4) US6180604B1 (de)
EP (1) EP0925308B1 (de)
JP (2) JP2001500477A (de)
AT (2) ATE410441T1 (de)
CA (1) CA2263799A1 (de)
DE (2) DE69713112T2 (de)
ES (2) ES2315252T3 (de)
HK (2) HK1021824A1 (de)
WO (1) WO1998007745A2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20000918A1 (en) * 1990-03-22 2001-05-30 Sloan Kettering Inst Cancer GP75 As a Tumor Vaccine for Melanoma
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
AU2605099A (en) * 1998-02-25 1999-09-15 Micrologix Biotech, Inc. Indolicidin and cationic peptides conjugated with polymers
US6303575B1 (en) 1998-05-12 2001-10-16 The Regents Of The University Of California Indolicidin analogs and methods of using same
WO1999065506A2 (en) * 1998-06-12 1999-12-23 Micrologix Biotech Inc. Cancer therapy with indolicidin or cationic peptides and their polymer conjugates
US6444645B1 (en) 1998-06-18 2002-09-03 The Regents Of The University Of California Crosslink-stabilized indolicidin analogs
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
JP2002530274A (ja) * 1998-10-30 2002-09-17 インターリンク・バイオテクノロジーズ・リミテッド・ライアビリティ・カンパニー プロテアーゼ分解に対する安定性の高いペプチド
US6946261B1 (en) * 1998-11-20 2005-09-20 Migenix Inc. Efficient methods for producing anti-microbial cationic peptides in host cells
EP1185623A4 (de) * 1999-03-03 2005-03-23 Regents Board Of Genetische und epigenetische manipulation von abc-transportern und ekto-phosphatasen zur vermittlung von arzneimittelresistenz und des verlustes von arzneimittelresistenz in biologischen systemen und verfahren zum nachweis von ekto-phosphatase-inhibitoren
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6576224B1 (en) 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6429211B1 (en) * 2000-05-23 2002-08-06 Bayer Corporation Praziquantel compounds for treating diseases due to Sarcocystis Neospora Toxoplasma and Isospora
CA2412011A1 (en) 2000-06-16 2001-12-27 Hercules Incorporated Chemically-modified antimicrobial peptides, compositions and methods of production and use
KR20090089922A (ko) 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
PT2301524E (pt) 2000-12-27 2013-07-10 Gilead Sciences Inc Aztreonam inalável sem arginina para tratamento e prevenção de infecções bacterianas pulmonares
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7115572B2 (en) * 2001-03-29 2006-10-03 Council Of Scientific And Industrial Research Indolicidin analogs with anti-microbial activity
US8658202B2 (en) 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
IL159274A0 (en) * 2001-06-22 2004-06-01 Hospital For Sick Children Antimicrobial peptides
US6835536B2 (en) * 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
US6734165B2 (en) * 2001-08-23 2004-05-11 The Trustees Of Columbia University In The City Of New York Method for re-sensitizing vancomycin resistant bacteria which selectively cleave a cell wall depsipeptide
AU2002328203C1 (en) 2001-08-24 2009-01-08 Migenix Inc. Antimicrobial and anti-inflammatory peptides
US20030219854A1 (en) * 2002-03-21 2003-11-27 Micrologix Biotech Inc. Methods for producing modified anti-infective peptides
WO2003087815A2 (en) * 2002-04-17 2003-10-23 Novartis Ag Method for the identification of inhibitors of the binding of are-containing mrn a and an hur protein
US7345018B2 (en) 2002-04-25 2008-03-18 Reception Aps Method of treating side effects induced by therapeutic agents
DE60335101D1 (de) * 2002-04-25 2011-01-05 Toagosei Co Ltd Antimikrobielles polypeptid und nutzung davon
IL150907A (en) * 2002-07-25 2007-07-04 Stephan Cherkez Process for the preparation of stable amorphous calcium pseudomonate
SE0202613D0 (sv) 2002-09-04 2002-09-04 Innate Pharmaceuticals Ab Förfarande och prob för identifiering av ämnen som modifierar bakteriers virulens, som sådana identifierade ämnen samt deras användning
US7238669B2 (en) * 2002-09-11 2007-07-03 The Curators Of The University Of Missouri Phage-display peptides as novel antimicrobial agents against Haemophilus influenzae
US20050245582A1 (en) * 2002-09-12 2005-11-03 The Hartz Mountain Corporation High concentration topical insecticides containing pyrethroids
US20060276339A1 (en) * 2002-10-16 2006-12-07 Windsor J B Methods and compositions for increasing the efficacy of biologically-active ingredients
US7589078B2 (en) 2003-02-19 2009-09-15 Yale University Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections
US20040260454A1 (en) * 2003-06-11 2004-12-23 Basir Otman A. Vibro-acoustic engine diagnostic system
US7189403B2 (en) * 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
US20050171063A1 (en) * 2003-10-20 2005-08-04 Pawan Malhotra Use of phosphono derivatives as anti-malarials
CN1901896B (zh) * 2003-10-22 2011-04-20 印度科学工业研究所 精选氨基酸锌复合物在制备抗疟疾药物中的应用
JP4524671B2 (ja) * 2003-10-29 2010-08-18 東亞合成株式会社 抗菌ペプチド及びその利用
WO2005089738A2 (en) * 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
US7994225B2 (en) * 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
US20050282755A1 (en) * 2004-03-18 2005-12-22 Ansata Therapeutics, Inc. Compositions having antimicrobial activity and uses thereof
AU2005269753B2 (en) 2004-07-19 2011-08-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
JP4507080B2 (ja) * 2004-07-30 2010-07-21 東亞合成株式会社 抗菌ペプチド及びその利用
US20080242734A1 (en) * 2004-08-06 2008-10-02 Chung Yuan Christian University Use of Biocistronic DNA Constructs for Identifying Compounds that Inhibit IRES-Dependent Translation
WO2006036625A2 (en) * 2004-09-24 2006-04-06 The Hartz Mountain Corporation Encapsulated pharmaceutical agents
JP4730584B2 (ja) 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
EP1849474B1 (de) * 2005-02-15 2016-09-07 Toagosei Co., Ltd. Antimikrobielles peptid und verwendung davon
WO2007014372A2 (en) 2005-07-28 2007-02-01 Biosynexus Incorporated Compositions and methods for treating bacteria
US20090099062A1 (en) * 2007-05-31 2009-04-16 Ethan Lee Pyrvinium For The Treatment of Cancer
PT2203181T (pt) 2007-10-16 2018-05-10 Biocon Ltd Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico
EP2296685B1 (de) * 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
JP2011195451A (ja) * 2008-06-20 2011-10-06 Fukuoka Univ ペプチド
US8773662B2 (en) * 2010-07-22 2014-07-08 Vuv Analytics, Inc. Methods and apparatus for vacuum ultraviolet (VUV) or shorter wavelength circular dichroism spectroscopy
DK2600869T3 (da) * 2010-08-05 2020-11-16 Helperby Therapeutics Ltd Kombination af en pyrroloquinolinforbindelse og et beta-lactam-antimikrobielt middel, mupirocin eller chlorhexidin
CN102167731B (zh) * 2011-02-10 2013-01-23 周逸明 一种固相多肽合成奥米加南的制备方法
US9487476B2 (en) 2011-10-12 2016-11-08 Yale University Catechol diethers as potent anti-HIV agents
DK3030549T3 (da) 2013-09-12 2019-05-13 Janssen Biopharma Inc Pyridazinonforbindelser og anvendelser deraf
WO2015077057A1 (en) * 2013-11-20 2015-05-28 Texas Southern University Methionine aminopeptidase inhibitors for treating infectious diseases
RU2678985C2 (ru) * 2017-02-06 2019-02-05 Общество с ограниченной ответственностью "Научно-производственная фирма ВЕРТА" Биоцидный пептид и препарат на его основе
CN108721292B (zh) * 2018-05-04 2022-04-01 中国疾病预防控制中心病毒病预防控制所 扑蛲灵在制备广谱抗冠状病毒药物中的应用
KR102433665B1 (ko) * 2021-11-17 2022-08-19 주식회사 씨위드 인돌리시딘 유래 항균 펩타이드 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
NZ237202A (en) 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
US5324716A (en) 1991-06-14 1994-06-28 Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
US5547939A (en) 1991-06-14 1996-08-20 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
US5593866A (en) 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
CA2172245C (en) 1993-09-22 2003-04-08 Jonathan Cohen Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein
AU680702B2 (en) * 1993-10-25 1997-08-07 Transave, Inc. Liposomal defensins
ATE219684T1 (de) 1994-01-14 2002-07-15 Xoma Technology Ltd Anti gram positive bakterielle verfahren und mittel
US5574017A (en) * 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US5877274A (en) 1995-06-02 1999-03-02 University Of British Columbia Antimicrobial cationic peptides
CA2230160A1 (en) 1995-08-23 1997-03-06 The University Of British Columbia Antimicrobial cationic peptides and methods of screening for the same
US5994308A (en) 1996-02-28 1999-11-30 Board Of Trustees Of Southern Illinois University Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6551994B1 (en) 1997-04-10 2003-04-22 Mcgill University Compounds and methods for inhibiting the interaction between α-catenin and β-catenin
AU2605099A (en) 1998-02-25 1999-09-15 Micrologix Biotech, Inc. Indolicidin and cationic peptides conjugated with polymers

Also Published As

Publication number Publication date
ES2178000T3 (es) 2002-12-16
HK1021824A1 (en) 2000-07-07
WO1998007745A2 (en) 1998-02-26
JP2001500477A (ja) 2001-01-16
EP0925308A2 (de) 1999-06-30
US6538106B1 (en) 2003-03-25
EP0925308B1 (de) 2002-06-05
JP4073900B2 (ja) 2008-04-09
ATE410441T1 (de) 2008-10-15
US20040009910A1 (en) 2004-01-15
ATE218579T1 (de) 2002-06-15
JP2005225857A (ja) 2005-08-25
ES2315252T3 (es) 2009-04-01
HK1043475B (zh) 2009-07-03
WO1998007745A3 (en) 1998-07-09
US6180604B1 (en) 2001-01-30
US20080242614A1 (en) 2008-10-02
CA2263799A1 (en) 1998-02-26
HK1043475A1 (en) 2002-09-13
DE69713112T2 (de) 2003-01-30
US7390787B2 (en) 2008-06-24
DE69739035D1 (de) 2008-11-20

Similar Documents

Publication Publication Date Title
DE69713112D1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
ATE333464T1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
MX9305729A (es) Formulas de proteinas de liberacion sostenida.
ATE481480T1 (de) Methoden und zusammensetzungen zur herstellung von polypeptiden
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
ATE352617T1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE60023860D1 (de) Verfahren zur herstellung von rekombinanten peptiden
DE69900756D1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
DK0896615T3 (da) Peptid fra opløselig form af acetylcholinesterase, der er aktivt som calcium-kanal-modulator
DK525384D0 (da) Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
DE69735583D1 (de) Semisynthetisches verfahren zur herstellung von didemninanalogen
EP1174439A3 (de) Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen
DE69938130D1 (de) Neue peptide
SE9602822D0 (sv) New receptor
ATE452903T1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
DE59108261D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
PL355852A1 (en) Fragments of virus protein vp2 or 3 of the polyoma virus, used for transporting active ingredients
SE9604439D0 (sv) New receptor
ATE179182T1 (de) Arginin ahnliche derivate als enzym-inhibitoren
FR2654430B1 (fr) Nouveaux derives de peptides, utilisables comme inhibiteurs des collagenases bacteriennes.
HUP9601528A2 (hu) Véralvadásgátló hatású peptidszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
8364 No opposition during term of opposition